Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468208 · ClinicalTrials.gov registry record · Phase 1
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
A Phase 1 study of Wegener's Granulomatosis, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT00468208 is a Phase 1 study of Wegener's Granulomatosis that has completed, run by University of Pennsylvania. The registered enrollment target is 20 participants, below the 72-participant average among 7 other Wegener's Granulomatosis trials with a reported enrollment target (72% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00468208, a Phase 1 study of Wegener's Granulomatosis, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
Wegener's granulomatosis (WG) is a rare disease that causes inflammation of blood vessels, or vasculitis. It may involve many different parts of the body, but typically affects the upper and lower respiratory tract and kidneys. The purpose of this study is to determine the safety and effectiveness of the medication abatacept in treating adults with mild relapsing WG.
Conditions Studied
Interventions
- DRUG Abatacept
Study Locations (4)
Maryland
- The Johns Hopkins Vasculitis Center - Baltimore
Massachusetts
- Boston University School of Medicine - Boston
Minnesota
- Mayo Clinic College of Medicine - Rochester
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00468208
The ClinicalTrials.gov registry entry for NCT00468208 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 7 other Wegener's Granulomatosis trials with a reported enrollment target (72% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Wegener's Granulomatosis appearing as the primary indexed condition, and to 1 intervention - of which Abatacept is the first listed.
NCT00468208 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00468208 about?
NCT00468208 is a clinical study titled "Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis". Wegener's granulomatosis (WG) is a rare disease that causes inflammation of blood vessels, or vasculitis. It may involve many different parts of the body, but typically affects the upper and lower respiratory tract and kidneys. The purpose of this study is to determine the safety and effectiveness o...
What is the current status of trial NCT00468208?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2008-02. Estimated completion is 2011-08.
What conditions does trial NCT00468208 study?
This clinical trial studies the following conditions: Wegener's Granulomatosis.
What interventions are being tested in trial NCT00468208?
The interventions under investigation include: Abatacept (DRUG).
Who is sponsoring clinical trial NCT00468208?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00468208 being conducted?
This trial has 4 study locations across Maryland, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wegener's Granulomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
COMPLETED · Phase 1
-
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
COMPLETED · Phase 1
-
Vasculitis Pregnancy Registry
RECRUITING
-
Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
COMPLETED · Phase 2
-
Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
COMPLETED · Phase 3
-
Etanercept to Treat Wegener's Granulomatosis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.